Accuri Raises $5M in Venture Funds for Cytometer Launch
Accuri Cytometers said this week that it has netted $5 million in Series B financing from Baird Venture Partners and Arboretum Ventures.
Accuri said it will use the money to accelerate the full commercial launch of its C6 flow cytometer system.
The C6 system is targeted toward labs that require flow cytometry hardware but lack the funds to buy a high-priced instrument. Accuri plans to market the product for under $30,000 [CBAN 12-15-06].
CEO Jennifer Baird said in a statement that the funding will "carry Accuri through broader beta testing and position us for full commercial launch next year."
Accuri also said that BVP's Pete Shagory and Arboretum's Tim Peterson have joined its board of directors.
ReNeuron Receives Notice of Allowance for European Stem Cell Line Patent
ReNeuron said this week that it has received a notification of allowance from the European Patent Office regarding its patent application covering the composition, manufacture, and use of three human neural stem cell lines.
The company’s patent application, EPO No. 05255932, contains claims covering the production of the cell lines and their use as a treatment for neurological disease, as well as their use in non-therapeutic applications such as cell-based screens for testing neurological drug candidates.
ReNeuron said that it has filed “equivalent patent applications” in the US and elsewhere.